Bcl-2 family of proteins as therapeutic targets in genitourinary neoplasms

Clinical Genitourinary Cancer

Volumn 11, Issue 1, 2013, Pages 10-19

  Hall, Connor ^a   Troutman, Sarah M ^b   Price, Douglas K ^b   Figg, William D ^b   Kang, Min H ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Apoptosis; Bcl 2 inhibitors

Indexed keywords

2 AMINO 6 BROMO 4 (1 CYANO 2 ETHOXY 2 OXOETHYL) 4H CHROMENE 3 CARBOXYLIC ACID ETHYL ESTER; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOCETAXEL; ETOPOSIDE; FLUDARABINE; GOSSYPOL; ISOSORBIDE; MITOMYCIN; MITOXANTRONE; OBATOCLAX; OBLIMERSEN; PACLITAXEL; PREDNISONE; PROTEIN BCL 2; VINBLASTINE;

ANDROGEN DEPRIVATION THERAPY; BLADDER CANCER; CANCER CELL CULTURE; CANCER PROGNOSIS; DEVELOPMENTAL STAGE; DISEASE ACTIVITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MECHANISM; GASTROINTESTINAL TOXICITY; HUMAN; KIDNEY CARCINOMA; NEUTROPENIA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; THROMBOCYTOPENIA; UROGENITAL TRACT CANCER;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIPHENYL COMPOUNDS; CLINICAL TRIALS AS TOPIC; GOSSYPOL; HUMANS; MOLECULAR TARGETED THERAPY; NITROPHENOLS; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-BCL-2; SULFONAMIDES; THIONUCLEOTIDES; UROGENITAL NEOPLASMS;

EID: 84874547247     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2012.09.002     Document Type: Review

References (109)

1. D. Hanahan, R.A. Weinberg Hallmarks of cancer: the next generation Cell 144 2011 646 674
2. D.R. Green, J.C. Reed Mitochondria and apoptosis Science 281 1998 1309 1312
3. M.H. Kang, C.P. Reynolds Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy Clin Cancer Res 15 2009 1126 1132
4. Y. Tsujimoto, J. Cossman, E. Jaffe Involvement of the bcl-2 gene in human follicular lymphoma Science 228 1985 1440 1443
5. P.N. Kelly, A. Strasser The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy Cell Death Differ 18 2011 1414 1424
6. Y. Furuya, S. Krajewski, J.I. Epstein Expression of bcl-2 and the progression of human and rodent prostatic cancers Clin Cancer Res 2 1996 389 398
7. M. Konopleva, S. Zhao, W. Hu The anti-apoptotic genes Bcl-X(L) and Bcl-2 are over-expressed and contribute to chemoresistance of non-proliferating leukaemic CD34+ cells Br J Haematol 118 2002 521 534
8. J. Pammer, M. Exner, H. Regele Expression of bcl-2, bcl-x, bax and bak in renal parenchyma, oncocytomas and renal cell carcinomas Pathol Res Pract 194 1998 837 845
9. A. Huang, P.D. Fone, R. Gandour-Edwards Immunohistochemical analysis of BCL-2 protein expression in renal cell carcinoma J Urol 162 1999 610 613
10. S.H. Glick, L.P. Howell, R.W. White Relationship of p53 and bcl-2 to prognosis in muscle-invasive transitional cell carcinoma of the bladder J Urol 155 1996 1754 1757
11. J.A. Karam, Y. Lotan, P.I. Karakiewicz Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy Lancet Oncol 8 2007 128 136
12. R. Siegel, D. Naishadham, A. Jemal Cancer statistics CA Cancer J Clin 2012 2012 10 29
13. Y. Meng, W. Tang, Y. Dai Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of puma and noxa Mol Cancer Ther 7 2008 2192 2202
14. I.F. Tannock, R. de Wit, W.R. Berry Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 2004 1502 1512
15. B. Seruga, I.F. Tannock Chemotherapy-based treatment for castration-resistant prostate cancer J Clin Oncol 29 2011 3686 3694
16. C.S. Higano, E.D. Crawford New and emerging agents for the treatment of castration-resistant prostate cancer Urol Oncol 29 2011 1 8
17. M. Colombel, F. Symmans, S. Gil Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers Am J Pathol 143 1993 390 400
18. D.M. Hockenbery, M. Zutter, W. Hickey BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death Proc Natl Acad Sci U S A 88 1991 6961 6965
19. M. Krajewska, S. Krajewski, J.I. Epstein Immunohistochemical analysis of bcl-2, bax, bcl-X, and Mcl-1 expression in prostate cancers Am J Pathol 148 1996 1567 1576
20. T.J. McDonnell, P. Troncoso, S.M. Brisbay Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer Cancer Res 52 1992 6940 6944
21. C.J. Rosser, A.O. Reyes, F. Vakar-Lopez Bcl-2 is significantly overexpressed in localized radio-recurrent prostate carcinoma, compared with localized radio-naive prostate carcinoma Int J Radiat Oncol Biol Phys 56 2003 1 6
22. D.J. McConkey, G. Greene, C.A. Pettaway Apoptosis resistance increases with metastatic potential in cells of the human LNCaP prostate carcinoma line Cancer Res 56 1996 5594 5599
23. S.R. Denmeade, X.S. Lin, J.T. Isaacs Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer Prostate 28 1996 251 265
24. S.D. Catz, J.L. Johnson Transcriptional regulation of bcl-2 by nuclear factor kappa B and its significance in prostate cancer Oncogene 20 2001 7342 7351
25. J. Lin, R.M. Adam, E. Santiestevan The phosphatidylinositol 3'-kinase pathway is a dominant growth factor-activated cell survival pathway in LNCaP human prostate carcinoma cells Cancer Res 59 1999 2891 2897
26. H. Murillo, H. Huang, L.J. Schmidt Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state Endocrinology 142 2001 4795 4805
27. A.J. Raffo, H. Perlman, M.W. Chen Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo Cancer Res 55 1995 4438 4445
28. A. Huang, R. Gandour-Edwards, S.A. Rosenthal p53 and bcl-2 immunohistochemical alterations in prostate cancer treated with radiation therapy Urology 51 1998 346 351
29. T.J. Mackey, A. Borkowski, P. Amin bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with prostate cancer Urology 52 1998 1085 1090
30. N. Howlader, A.M. Noone, M. Krapcho SEER cancer statistics review, 1975-2008 Bethesda, MD: National Cancer Institute, SEER Program http://seer.cancer.gov/csr/1975-2008/ Accessed: May 25, 2011
31. A. Yagoda, B. Abi-Rached, D. Petrylak Chemotherapy for advanced renal-cell carcinoma: 1983-1993 Semin Oncol 22 1995 42 60
32. C. Coppin, C. Kollmannsberger, L. Le Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials BJU Int 108 2011 1556 1563
33. C.T. Lee, E.M. Genega, B. Hutchinson Conventional (clear cell) renal carcinoma metastases have greater bcl-2 expression than high-risk primary tumors Urol Oncol 21 2003 179 184
34. T. Itoi, K. Yamana, V. Bilim Impact of frequent Bcl-2 expression on better prognosis in renal cell carcinoma patients Br J Cancer 90 2004 200 205
35. N.B. Phuoc, H. Ehara, T. Gotoh Immunohistochemical analysis with multiple antibodies in search of prognostic markers for clear cell renal cell carcinoma Urology 69 2007 843 848
36. I. Sturm, C. Stephan, B. Gillissen Loss of the tissue-specific proapoptotic BH3-only protein Nbk/Bik is a unifying feature of renal cell carcinoma Cell Death Differ 13 2006 619 627
37. N. Zantl, G. Weirich, H. Zall Frequent loss of expression of the pro-apoptotic protein Bim in renal cell carcinoma: evidence for contribution to apoptosis resistance Oncogene 26 2007 7038 7048
38. C. Kempkensteffen, S. Hinz, M. Johannsen Expression of Mcl-1 splicing variants in clear-cell renal cancer and their correlation with histopathological parameters and prognosis Tumour Biol 30 2009 73 79
39. X. Zhang, I. Takenaka Cell proliferation and apoptosis with BCL-2 expression in renal cell carcinoma Urology 56 2000 510 515
40. K.S. Ahn, E. Bae, S.S. Jeon Microenvironment effects on promoting upregulation of matrix metalloproteinases in Bcl-2-overexpressing renal cell carcinoma as a response to doxorubicin treatment inducing the production of metastasis Tumour Biol 28 2007 181 188
41. V. Bilim, K. Yuuki, T. Itoi Double inhibition of XIAP and Bcl-2 axis is beneficial for retrieving sensitivity of renal cell cancer to apoptosis Br J Cancer 98 2008 941 949
42. I. Kausch, H. Jiang, B. Thode Inhibition of bcl-2 enhances the efficacy of chemotherapy in renal cell carcinoma Eur Urol 47 2005 703 709
43. J.D. Kelly, J. Dai, P. Eschwege Downregulation of Bcl-2 sensitises interferon-resistant renal cancer cells to Fas Br J Cancer 91 2004 164 170
44. J.H. Song, K. Kandasamy, M. Zemskova The BH3 mimetic ABT-737 induces cancer cell senescence Cancer Res 71 2011 506 515
45. H. Zall, A. Weber, R. Besch Chemotherapeutic drugs sensitize human renal cell carcinoma cells to ABT-737 by a mechanism involving the noxa-dependent inactivation of Mcl-1 or A1 Mol Cancer 9 2010 164
46. Z. Kirkali, T. Chan, M. Manoharan Bladder cancer: epidemiology, staging and grading, and diagnosis Urology 66 2005 4 34
47. M.S. Soloway, M. Sofer, A. Vaidya Contemporary management of stage T1 transitional cell carcinoma of the bladder J Urol 167 2002 1573 1583
48. H. von der Maase, L. Sengelov, J.T. Roberts Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer J Clin Oncol 23 2005 4602 4608
49. J. Bellmunt, H. von der Maase, G.M. Mead Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC intergroup study 30987 J Clin Oncol 30 2012 1107 1113
50. P.J. Loehrer, L.H. Einhorn, P.J. Elson A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study J Clin Oncol 10 1992 1066 1073
51. C.J. Logothetis, L.D. Finn, T. Smith Escalated MVAC with or without recombinant human granulocyte-macrophage colony-stimulating factor for the initial treatment of advanced malignant urothelial tumors: results of a randomized trial J Clin Oncol 13 1995 2272 2277
52. E.D. King, J. Matteson, S.C. Jacobs Incidence of apoptosis, cell proliferation and bcl-2 expression in transitional cell carcinoma of the bladder: association with tumor progression J Urol 155 1996 316 320
53. I. Giannopoulou, L. Nakopoulou, A. Zervas Immunohistochemical study of pro-apoptotic factors Bax, Fas and CPP32 in urinary bladder cancer: prognostic implications Urol Res 30 2002 342 345
54. S.A. Hussain, R. Ganesan, L. Hiller BCL2 expression predicts survival in patients receiving synchronous chemoradiotherapy in advanced transitional cell carcinoma of the bladder Oncol Rep 10 2003 571 576
55. F. Ong, L.M. Moonen, M.P. Gallee Prognostic factors in transitional cell cancer of the bladder: an emerging role for Bcl-2 and p53 Radiother Oncol 61 2001 169 175
56. A. Stenzl, N.C. Cowan, M. De Santis Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines Eur Urol 59 2011 1009 1018
57. H.J. Cho, J.K. Kim, K.D. Kim Upregulation of Bcl-2 is associated with cisplatin-resistance via inhibition of Bax translocation in human bladder cancer cells Cancer Lett 237 2006 56 66
58. H. Miyake, N. Hanada, H. Nakamura Overexpression of Bcl-2 in bladder cancer cells inhibits apoptosis induced by cisplatin and adenoviral-mediated p53 gene transfer Oncogene 16 1998 933 943
59. D. Karnak, L. Xu Chemosensitization of prostate cancer by modulating Bcl-2 family proteins Curr Drug Targets 11 2010 699 707
60. K.N. Chi Targeting Bcl-2 with oblimersen for patients with hormone refractory prostate cancer World J Urol 23 2005 33 37
61. G. Marcucci, B. Moser, W. Blum A phase III randomized trial of intensive induction and consolidation chemotherapy (+/-) oblimersen, a pro-apoptotic Bcl-2 antisense oligonucleotide in untreated acute myeloid leukemia patients >60 years old J Clin Oncol 25 2007 7012
62. S. O'Brien, J.O. Moore, T.E. Boyd Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia J Clin Oncol 25 2007 1114 1120
63. A.A. Chanan-Khan, R. Niesvizky, R.J. Hohl Phase III randomised study of dexamethasone with or without oblimersen sodium for patients with advanced multiple myeloma Leuk Lymphoma 50 2009 559 565
64. M. Gleave, A. Tolcher, H. Miyake Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model Clin Cancer Res 5 1999 2891 2898
65. S. Haldar, J. Chintapalli, C.M. Croce Taxol induces bcl-2 phosphorylation and death of prostate cancer cells Cancer Res 56 1996 1253 1255
66. K.N. Chi, M.E. Gleave, R. Klasa A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer Clin Cancer Res 7 2001 3920 3927
67. A.W. Tolcher, J. Kuhn, G. Schwartz A phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer Clin Cancer Res 10 2004 5048 5057
68. A.W. Tolcher, K. Chi, J. Kuhn A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer Clin Cancer Res 11 2005 3854 3861
69. C.N. Sternberg, H. Dumez, H. Van Poppel Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer Ann Oncol 20 2009 1264 1269
70. K. Margolin, T.W. Synold, P. Lara Oblimersen and alpha-interferon in metastatic renal cancer: a phase II study of the California Cancer Consortium J Cancer Res Clin Oncol 133 2007 705 711
71. B.J. Duggan, P. Maxwell, J.D. Kelly The effect of antisense Bcl-2 oligonucleotides on Bcl-2 protein expression and apoptosis in human bladder transitional cell carcinoma J Urol 166 2001 1098 1105
72. J.A. Macoska, S. Adsule, K. Tantivejkul -(-)Gossypol promotes the apoptosis of bladder cancer cells in vitro Pharmacol Res 58 2008 323 331
73. M.N. Stein, I. Khan, M. Hussain Phase II study of AT-101 to abrogate Bcl-2-mediated resistance to androgen-deprivation therapy (ADT) in patients (pts) with newly diagnosed androgen-dependent metastatic prostate cancer (ADMPC) ASCO Meeting Abstracts 29 2011 137
74. G. Sonpavde, V. Matveev, J.M. Burke Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer Ann Oncol 23 2012 1803 1808
75. G. Liu, W.K. Kelly, G. Wilding An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer Clin Cancer Res 15 2009 3172 3176
76. S. Anai, B.D. Brown, K. Nakamura Irradiation of human prostate cancer cells increases uptake of antisense oligodeoxynucleotide Int J Radiat Oncol Biol Phys 68 2007 1161 1168
77. M. Rubenstein, P. Tsui, P. Guinan Treatment of prostate and breast tumors employing mono- and bi-specific antisense oligonucleotides targeting apoptosis inhibitory proteins clusterin and bcl-2 Med Oncol 27 2010 592 599
78. Y.W. Huang, L.S. Wang, H.L. Chang Molecular mechanisms of (-)-gossypol-induced apoptosis in human prostate cancer cells Anticancer Res 26 2006 1925 1933
79. S. Liu, S.K. Kulp, Y. Sugimoto The (-)-enantiomer of gossypol possesses higher anticancer potency than racemic gossypol in human breast cancer Anticancer Res 22 2002 33 38
80. G.P. Tuszynski, G. Cossu Differential cytotoxic effect of gossypol on human melanoma, colon carcinoma, and other tissue culture cell lines Cancer Res 44 1984 768 771
81. J.W. Jaroszewski, O. Kaplan, J.S. Cohen Action of gossypol and rhodamine 123 on wild type and multidrug-resistant MCF-7 human breast cancer cells: 31P nuclear magnetic resonance and toxicity studies Cancer Res 50 1990 6936 6943
82. P.N. Rao, Y.C. Wang, E. Lotzova Antitumor effects of gossypol on murine tumors Cancer Chemother Pharmacol 15 1985 20 25
83. W.W. Tso Gossypol inhibits Ehrlich ascites tumor cell proliferation Cancer Lett 24 1984 257 261
84. L. Xu, D. Yang, S. Wang (-)-gossypol enhances response to radiation therapy and results in tumor regression of human prostate cancer Mol Cancer Ther 4 2005 197 205
85. J. Lian, X. Wu, F. He A natural BH3 mimetic induces autophagy in apoptosis-resistant prostate cancer via modulating Bcl-2-Beclin1 interaction at endoplasmic reticulum Cell Death Differ 18 2011 60 71
86. E. Cengiz, B. Karaca, Y. Kucukzeybek Overcoming drug resistance in hormone- and drug-refractory prostate cancer cell line, PC-3 by docetaxel and gossypol combination Mol Biol Rep 37 2010 1269 1277
87. N. McGregor, L. Patel, M. Craig AT-101 (R-(-)-gossypol acetic acid) enhances the effectiveness of androgen deprivation therapy in the VCaP prostate cancer model J Cell Biochem 110 2010 1187 1194
88. S.R. Volate, B.T. Kawasaki, E.M. Hurt Gossypol induces apoptosis by activating p53 in prostate cancer cells and prostate tumor-initiating cells Mol Cancer Ther 9 2010 461 470
89. Y. Zhao, M. Gounder, H. Lin Phase I study of at-101 (R-(-)-gossypol) in combination with paclitaxel (P) and carboplatin (C) in solid tumors including castrate-resistant prostate cancer (CRPC) ASCO Meeting Abstracts 29 2011 169
90. Y. Zhan, G. Jia, D. Wu Design and synthesis of a gossypol derivative with improved antitumor activities Arch Pharm (Weinheim) 342 2009 223 229
91. C. Zhang, T.Y. Cai, H. Zhu Synergistic antitumor activity of gemcitabine and ABT-737 in vitro and in vivo through disrupting the interaction of USP9X and Mcl-1 Mol Cancer Ther 10 2011 1264 1275
92. R. Dash, B. Azab, B.A. Quinn Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda-7/IL-24-mediated toxicity Proc Natl Acad Sci U S A 108 2011 8785 8790
93. T. Oltersdorf, S.W. Elmore, A.R. Shoemaker An inhibitor of Bcl-2 family proteins induces regression of solid tumours Nature 435 2005 677 681
94. B. Pandit, A.L. Gartel New potential anti-cancer agents synergize with bortezomib and ABT-737 against prostate cancer Prostate 70 2010 825 833
95. C. Tse, A.R. Shoemaker, J. Adickes ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor Cancer Res 68 2008 3421 3428
96. L. Gandhi, D.R. Camidge, M. Ribeiro de Oliveira Phase I study of navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors J Clin Oncol 29 2011 909 916
97. K.D. Mason, M.R. Carpinelli, J.I. Fletcher Programmed anuclear cell death delimits platelet life span Cell 128 2007 1173 1186
98. S.M. Schoenwaelder, K.E. Jarman, E.E. Gardiner Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets Blood 118 2011 1663 1674
99. C.M. Rudin, C.L. Hann, E.B. Garon Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer Clin Cancer Res 18 2012 3163 3169
100. J.W. Hao, X.P. Mao, D.G. Ding The effect of cell killing by ABT-737 synergized with docetaxel in human prostate cancer PC-3 cells [in Chinese] Zhonghua Wai Ke Za Zhi 50 2012 161 165
101. J.H. Song, A.S. Kraft Pim kinase inhibitors sensitize prostate cancer cells to apoptosis triggered by Bcl-2 family inhibitor ABT-737 Cancer Res 72 2012 294 303
102. R. Yamaguchi, E. Janssen, G. Perkins Efficient elimination of cancer cells by deoxyglucose-ABT-263/737 combination therapy PLoS One 6 2011 e24102
103. J.L. Wang, D. Liu, Z.J. Zhang Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells Proc Natl Acad Sci U S A 97 2000 7124 7129
104. J. An, A.S. Chervin, A. Nie Overcoming the radioresistance of prostate cancer cells with a novel Bcl-2 inhibitor Oncogene 26 2007 652 661
105. S. Heikaus, I. Pejin, H.E. Gabbert PIDDosome expression and the role of caspase-2 activation for chemotherapy-induced apoptosis in RCCs Cell Oncol 32 2010 29 42
106. S. Heikaus, L. van den Berg, T. Kempf HA14-1 is able to reconstitute the impaired mitochondrial pathway of apoptosis in renal cell carcinoma cell lines Cell Oncol 30 2008 419 433
107. D. Tian, S.G. Das, J.M. Doshi sHA 14-1, a stable and ROS-free antagonist against anti-apoptotic Bcl-2 proteins, bypasses drug resistances and synergizes cancer therapies in human leukemia cell Cancer Lett 259 2008 198 208
108. S. Ray, O. Bucur, A. Almasan Sensitization of prostate carcinoma cells to Apo2L/TRAIL by a Bcl-2 family protein inhibitor Apoptosis 10 2005 1411 1418
109. M. Nguyen, R.C. Marcellus, A. Roulston Small molecule obatoclax (GX15-070) antagonizes Mcl-1 and overcomes Mcl-1-mediated resistance to apoptosis Proc Natl Acad Sci U S A 104 2007 19512 19517